6月23日，诺和诺德（Novo Nordisk）股价在盘前交易中大跌5.08%，报70.87美元。这一跌幅主要源于公司新型减肥药物CagriSema的临床试验数据未能完全达到市场预期。
诺和诺德在美国糖尿病协会年会上公布了CagriSema两项Ⅲ期临床试验的完整数据。结果显示，接受CagriSema治疗的超重或肥胖非糖尿病患者平均减重约23%，2型糖尿病合并超重患者减重15.8%。虽然这一效果优于公司现有产品，但未能显著超越竞争对手礼来公司的同类药物Tirzepatide，后者在72周试验中实现了22%的减重幅度。
安全性方面，79.6%的CagriSema使用者出现胃肠道不良反应，高于安慰剂组的39.9%。虽然大多数副作用为轻中度且为暂时性，但仍有6%的受试者因不良事件提前终止治疗。这些数据引发了投资者对药物市场竞争力的担忧，导致股价下跌。尽管如此，诺和诺德仍计划于2026年初向FDA提交CagriSema的上市申请，预计最快可在2027年初上市。这款新药能否帮助诺和诺德在激烈的减肥药市场中保持领先地位，仍有待进一步观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.